BioNTech Shares Face Mounting Pressure Amid Strategic Pivot

The equity of German biotechnology firm BioNTech is navigating a period of significant volatility. As the company accelerates its strategic transformation into a fully-fledged oncology-focused enterprise, its stock price has recently breached a critical long-term technical level. This comes ahead of the scheduled release of its 2025 annual figures on March 10, an event that will offer a crucial assessment of the foundation underlying this ambitious corporate shift.

Financial Position and Revised Forecasts

Providing a substantial buffer for its costly research initiatives, BioNTech reported liquid funds of €17.2 billion at the end of 2025. The company has also upwardly revised its revenue guidance for the full year 2025, now projecting between €2.6 billion and €2.8 billion. Concurrently, it has adjusted its projected expenses for research, administration, and capital investments downward.

However, management has indicated that it does not anticipate generating any revenue from oncology products in 2026. The immediate focus remains squarely on its development pipeline. This year, BioNTech plans to present data from seven late-stage clinical trials, five of which hold the potential to lead to regulatory approvals. By the end of the year, the company aims to be running 15 Phase III studies concurrently, targeting cancers including lung, breast, and other forms.

A Concerning Technical Breakdown

From a chart analysis perspective, a key warning signal was triggered when the stock price recently fell below its 200-day moving average, situated at $104.70. Shares closed at $100.76, marking a weekly decline of 9.1%. The loss extends to 11.4% over the past month and 8.1% since the start of the year.

Market observers note a telling trend: even announcements of positive strategic developments or encouraging clinical data have failed to generate sustained upward momentum in the share price recently. This pattern suggests a persistent sense of skepticism among investors.

Should investors sell immediately? Or is it worth buying BioNTech?

Strategic Moves to Build an Oncology Powerhouse

Following its successful COVID-19 vaccine partnership with Pfizer, BioNTech is decisively redirecting its core business toward cancer treatments. A major step in this direction was the acquisition of the Chinese biotech firm Biotheus, which brought the drug candidate BNT327 into its portfolio. This move proved immediately fruitful, leading to a co-development and commercialization agreement with Bristol Myers Squibb valued at up to $11.1 billion. An upfront payment of $1.5 billion has already been received, with a further $2 billion due by 2028.

In a separate deal in December 2025, BioNTech secured an 86.75% stake in CureVac. This acquisition is intended to bolster its mRNA technology platform and expand overall manufacturing capabilities.

Divergent Views from Market Experts

Analysts on Wall Street are divided in their assessments. In mid-January 2026, Goldman Sachs upgraded its rating on BioNTech, citing convincing execution of the company’s strategic roadmap. Conversely, Leerink downgraded the stock to “Market Perform” in early February, arguing that a previous price recovery had already exhausted near-term upside potential.

Adding a layer of uncertainty is an ongoing patent dispute with Moderna concerning mRNA technologies related to COVID-19 vaccines.

A Pivotal Period Ahead

The coming months are set to determine whether BioNTech can successfully transition from a vaccine specialist to a diversified oncology company. While the financial resources and an ambitious development pipeline are in place, the path is challenging. Management will present the final 2025 results and provide a strategic update on March 10 at 2:00 PM German time. This event is expected to bring greater clarity regarding the feasibility of the company’s stated objectives.